• The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis 

      Butzkueven, Helmut; Hillert, Jan; Soilu-Hänninen, Merja; Ziemssen, Tjalf; Kuhle, Jens; Wergeland, Stig; Magyari, Melinda; Berger, Joseph R.; Moore, Nicholas; Aydemir, Aida; Bezemer, Irene; Sabidó, Meritxell (Journal article; Peer reviewed, 2023)
      Objectives As part of the CLARION study: (1) characterize the incidence of severe infections, herpes zoster, and malignancies in patients newly initiating cladribine or fingolimod for relapsing multiple sclerosis (MS); ...
    • Neurofilament light chain predicts disease activity in relapsing-remitting MS 

      Varhaug, Kristin Nielsen; Barro, Christian; Bjørnevik, Kjetil Lauvland; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig; Bindoff, Laurence; Kuhle, Jens; Vedeler, Christian A. (Peer reviewed; Journal article, 2018)
      Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed ...